KRN 5500

Known as: 6-[4-Deoxy-4-[(2E,4E)-tetradecadienoylglycyl]amino-L-glycero-beta-L-mannohepto-pyranosyl]amino-9H-purine, KRN-5500, KRN5500 
A semisynthetic derivative of the nucleoside-like antineoplastic antibiotic spicamycin, originally isolated from the bacterium Streptomyces… (More)
National Institutes of Health

Related topics

Related topics

6 relations
Cell Differentiation processEndoplasmic ReticulumGolgi ApparatusPositive Regulation of Apoptosis
(More)

Broader (1)

Purine Nucleosides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2003
2003
KRN5500: a novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis.
Therapy of B-cell chronic lymphocytic leukemia (CLL) is currently palliative, emphasizing the need for identification of new… (More)
  • table 1
  • figure 3
  • figure 1
  • figure 2
  • figure 4
Is this relevant?
2002
2002
Incorporation of the Anticancer Agent KRN5500 into Polymeric Micelles Diminishes the Pulmonary Toxicity
KRN5500 is a highly active new semi-synthetic water-insoluble anticancer agent. The only mechanism of anticancer activity of… (More)
  • figure 1
  • table I
  • figure 2
  • figure 3
Is this relevant?
2001
2001
Population pharmacokinetic modeling and model validation of a spicamycin derivative, KRN5500, in phase 1 study
Purpose: KRN5500, a novel spicamycin derivative, shows the greatest activity against a human tumor xenograft model and the… (More)
Is this relevant?
2000
2000
Selective accumulation of the endoplasmic reticulum-Golgi intermediate compartment induced by the antitumor drug KRN5500.
KRN5500 is a semisynthetic spicamycin analogue consisting of a seven-carbon amino sugar linked to a C(14) unsaturated fatty acid… (More)
Is this relevant?
1999
1999
Reduction of the Side Effects of an Antitumor Agent, KRN5500, by Incorporation of the Drug into Polymeric Micelles
For intravenous (i.v.) injection of a water-insoluble antitumor drug, KRN5500, we have successfully incorporated KRN5500 into… (More)
  • figure 1
  • table I
  • figure 2
  • figure 3
  • table II
Is this relevant?
1999
1999
In vitro interactions of a new derivative of spicamycin, KRN5500, and other anticancer drugs using a three-dimensional model
Purpose: KRN5500 is a new derivative of spicamycin produced by Streptomyces alanosinicus and is known to have a wide range of… (More)
  • figure 2
  • table 1
  • table 2
  • figure 3
  • figure 4
Is this relevant?
Review
1997
Review
1997
[Protein synthesis inhibitor--antitumor activity and mode of action of KRN 5500].
KRN 5500 is a new semi-synthetic antitumor compound derived from spicamycin and has a unique structure. The compound showed a… (More)
Is this relevant?
1997
1997
Antiproliferative activity in vitro and in vivo of the spicamycin analogue KRN5500 with altered glycoprotein expression in vitro.
The spicamycin analogue KRN5500 (NSC 650426; SPA) is derived from Streptomyces alanosinicus. The unique structure contains a… (More)
  • figure I
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
1995
1995
In vitro cytotoxicity of a novel antitumor antibiotic, spicamycin derivative, in human lung cancer cell lines.
Spicamycin (SPM), produced by Streptomyces alanosinicus, induces potent differentiation in a human leukemia cell line, HL60. One… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
1994
1994
Antitumor activity of a spicamycin derivative, KRN5500, and its active metabolite in tumor cells.
KRN5500, (6-[4-Deoxy-4-(2E,4E)-tetradecadienoylglycyl]amino-L-glycero - beta-L-mannoheptopyranosyl]amino-9H-purine), was semi… (More)
Is this relevant?